Evidence map›Paper›PMID 37079341›Full record

SynthesisJournal of comparative effectiveness research2023

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.

Raj Hanvesakul, Badri Rengarajan, Navit Naveh, Anne Boccuti, Julie E Park, Adekemi Adeyemi, Clyde Caisip, Jeroen P Jansen, Florence R Wilson

Registry-linked trialOpen access · diamondAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of comparative effectiveness research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05257551 (Tempus SCLC Observational Study), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05257551 recruitingnot on this map

Tempus SCLC Observational Study: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays

Typeobservational_patient_registrySponsorTempus AIRan2022 to 2029Enrolled200ConditionsSmall Cell Lung CancerArmsObservation
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Raj HanvesakulJazz Pharmaceuticals, Oxford, England, OX4 2RW, UK.ORCID 0000-0003-1682-9203
Badri RengarajanJazz Pharmaceuticals, Palo Alto, CA 94304, USA.
Navit NavehJazz Pharmaceuticals, Philadelphia, PA 19103, USA.
Anne BoccutiJazz Pharmaceuticals, Philadelphia, PA 19103, USA.
Julie E ParkPRECISIONheor, Vancouver, BC, V6J1H2, Canada.ORCID 0000-0002-8054-5443
Adekemi AdeyemiPRECISIONheor, Vancouver, BC, V6J1H2, Canada.
Clyde CaisipPRECISIONheor, Vancouver, BC, V6J1H2, Canada.
Jeroen P JansenPRECISIONheor, Oakland, CA 94612, USA.
Florence R WilsonPRECISIONheor, Vancouver, BC, V6J1H2, Canada.
Jazz Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lung NeoplasmsSmall Cell Lung CarcinomaAntineoplastic Combined Chemotherapy ProtocolsCarbolinesHeterocyclic Compounds, 4 or More RingsHumansPlatinumRandomized Controlled Trials as TopicTopotecanCarbolinesHeterocyclic Compounds, 4 or More RingsPlatinumPM 01183Topotecanlurbinectedinmatching-adjusted indirect comparisonnetwork meta-analysisplatinum sensitivesmall-cell lung cancertopotecan

Identifiers

PMID37079341
PMCPMC10402758
OpenAlexW4366462822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.